B of A Securities Upgrades Ionis Pharmaceuticals to Buy, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Neutral to Buy and increased the price target from $52 to $62.
January 02, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals was upgraded by B of A Securities from Neutral to Buy, with a raised price target from $52 to $62.
Upgrades by analysts, especially from neutral to buy ratings, typically suggest a positive outlook on the stock and can lead to increased investor confidence and a potential rise in the stock price in the short term. The increase in the price target further supports a bullish view on the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100